<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160818</url>
  </required_header>
  <id_info>
    <org_study_id>RadOnc MRI TUM - 2</org_study_id>
    <nct_id>NCT05160818</nct_id>
  </id_info>
  <brief_title>Hypofractionated Versus Single Fraction Stereotactic Adjuvant Radiotherapy to the Resection Cavity of Brain Metastases</brief_title>
  <acronym>SATURNUS</acronym>
  <official_title>Hypofractionated Stereotactic Radiotherapy Versus Single Fraction Stereotactic Radiosurgery to the Resection Cavity of Brain Metastases After Surgical Resection - A Prospective, Randomized, Controlled, Monocentric Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized, controlled, monocentric clinical phase III study focuses on&#xD;
      stereotactic irradiation of resection cavities of brain metastases after surgical resection&#xD;
      and seeks to demonstrate the superiority of fractionated irradiation schemes in terms of&#xD;
      local control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a growing scientific focus on single fraction stereotactic (SRS) and&#xD;
      hypofractionated stereotactic irradiation (HFSRT) after surgical resection of brain&#xD;
      metastasis and its use is more frequently recommended in international guidelines. Despite&#xD;
      intensive research, the optimal fractionation scheme and dose prescription for adjuvant&#xD;
      irradiation of the resection cavity remains unclear.&#xD;
&#xD;
      Based on our own institutional data [Cit.1] and a recently published metaanalysis [Cit.2], we&#xD;
      hypothesize that local control (LC) after HFSRT is superior compared to SRS in terms of LC.&#xD;
      To evaluate the hypothesis in a prospective, randomized, controlled setting we designed the&#xD;
      SATURNUS study.&#xD;
&#xD;
      A total of 126 patients will be randomized 1:1 to either HFSRT (dose 6-7 x 5 Gy) or SRS (dose&#xD;
      1 x 12-20 Gy). If further unresected brain metastases are present, they will be treated with&#xD;
      SRS (1 x 14 - 22 Gy). Irradiation is carried out with a Gamma Knife or a Linear Accelerator.&#xD;
      In line with current clinical practice, the choice of positioning method for SRS with the&#xD;
      Gamma Knife (mask or stereotactic frame) is left to the patient. In the case of SRS with the&#xD;
      Linear Accelerator or HFSRT, fixation is done with a mask as technically not otherwise&#xD;
      feasible. Follow-up-MRI will be at least carried out 6 weeks and 3, 6, 9 and 12 months after&#xD;
      treatment. Primary endpoint of the study is local control (LC) at the irradiated resection&#xD;
      cavity after 12 months. Locoregional control (LRC) and overall survival (OS) as well as&#xD;
      salvage-treatments, irradiation-associated toxicities (especially rate of radionecrosis) and&#xD;
      quality-of-life parameters are investigated as secondary endpoints.&#xD;
&#xD;
      To the best of our knowledge, the SATURNUS study is the only randomized phase III study&#xD;
      comparing different techniques of postoperative stereotactic radiotherapy after resection of&#xD;
      brain metastases adequately powered to detect a superiority of HSFRT regarding LC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The affiliation to the treatment arm will not be blinded to anyone except the study neuroradiologist.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Local control</measure>
    <time_frame>12 months after adjuvant radiotherapy</time_frame>
    <description>Local control at the resected site(s)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LC</measure>
    <time_frame>12 months after adjuvant radiotherapy</time_frame>
    <description>Local control at all treated site(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LRC</measure>
    <time_frame>12 months after adjuvant radiotherapy</time_frame>
    <description>Locoregional control=CNS progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>12 months after adjuvant radiotherapy</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salvage-free survival</measure>
    <time_frame>12 months after adjuvant radiotherapy</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial salvage therapy</measure>
    <time_frame>12 months after adjuvant radiotherapy</time_frame>
    <description>Number and kind of intracranial salvage treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pseudoprogression</measure>
    <time_frame>up to 12 months after adjuvant radiotherapy</time_frame>
    <description>Rate of pseudoprogression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irradiation-related toxicity</measure>
    <time_frame>up to 12 months after adjuvant radiotherapy</time_frame>
    <description>according to CTCAE v4.03, especially rate of radionecrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>up to 12 months after adjuvant radiotherapy</time_frame>
    <description>Quality of life according to EORTC QLQ-C30 and EORTC QLQ-B20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to loss of independence</measure>
    <time_frame>up to 12 months after adjuvant radiotherapy</time_frame>
    <description>defined as decrease in Barthel index by &gt; 20 points</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Brain Metastases</condition>
  <condition>Resection Cavity</condition>
  <arm_group>
    <arm_group_label>Arm A: HSFRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypofractionated stereotactic radiotherapy to the resection cavity, dose prescription: 6-7 x 5 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: SRS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single fraction stereotactic radiotherapy to the resection cavity, dose prescription: 1 x 12-20 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiotherapy radiosurgery (SRS)</intervention_name>
    <description>intervention description see above</description>
    <arm_group_label>Arm A: HSFRT</arm_group_label>
    <arm_group_label>Arm B: SRS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor disease&#xD;
&#xD;
          -  One to three resected brain metastases&#xD;
&#xD;
          -  Consent to perform adjuvant irradiation by an interdisciplinary tumor board&#xD;
&#xD;
          -  Completed wound healing&#xD;
&#xD;
          -  Resection within the last six weeks at the time of study inclusion&#xD;
&#xD;
          -  Diameter of the resection cavity ≤ 4 cm (on Planning MRI)&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  KPS &gt; 60%&#xD;
&#xD;
          -  Adequate contraceptive measures for fertile women / men&#xD;
&#xD;
          -  Written informed consent (must be available before enrolment in the trial)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication for repetitive contrast enhanced MRI&#xD;
&#xD;
          -  Leptomeningeal disease&#xD;
&#xD;
          -  Small cell histology, hematological malignancies and / or germ cell malignancies&#xD;
&#xD;
          -  Previous irradiation of the brain&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Inability to understand the character and consequences of the study&#xD;
&#xD;
          -  Withdrawal of consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Waltenberger</last_name>
    <role>Study Director</role>
    <affiliation>Technical University Munich, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Waltenberger</last_name>
    <phone>+49-89-4140-8281</phone>
    <email>maria.waltenberger@mri.tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie E Combs, Prof. Dr.</last_name>
    <phone>+49-89-4140-4501</phone>
    <email>direktion.radonk@mri.tum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. Radiation Oncology</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie E. Combs, Prof. Dr.</last_name>
      <phone>089 4140 4501</phone>
      <email>direktion.radonk@mri.tum.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Specht HM, Kessel KA, Oechsner M, Meyer B, Zimmer C, Combs SE. HFSRT of the resection cavity in patients with brain metastases. Strahlenther Onkol. 2016 Jun;192(6):368-76. doi: 10.1007/s00066-016-0955-2. Epub 2016 Mar 10.</citation>
    <PMID>26964777</PMID>
  </reference>
  <reference>
    <citation>Akanda ZZ, Hong W, Nahavandi S, Haghighi N, Phillips C, Kok DL. Post-operative stereotactic radiosurgery following excision of brain metastases: A systematic review and meta-analysis. Radiother Oncol. 2020 Jan;142:27-35. doi: 10.1016/j.radonc.2019.08.024. Epub 2019 Sep 25.</citation>
    <PMID>31563407</PMID>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 6, 2021</study_first_submitted>
  <study_first_submitted_qc>December 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität München</investigator_affiliation>
    <investigator_full_name>Stephanie Combs</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr. med. Stephanie E. Combs</investigator_title>
  </responsible_party>
  <keyword>Brain Metastases</keyword>
  <keyword>Resection Cavity</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Stereotactic Irradiation</keyword>
  <keyword>Gamma Knife</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

